Novartis Strikes $125M Deal For Chinese Vaccine Co.
Novartis AG has increased its presence in the booming Chinese drug market by purchasing a majority stake in vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd. for $125 million, the Swiss drug...To view the full article, register now.
Already a subscriber? Click here to view full article